IL-1α & IL-1β inhibition with ARCALYST is increasingly becoming the preferred second line treatment for patients with recurrent pericarditis, with approximately 18% of the multiple recurrence population actively on ARCALYST therapy as of end-2025. The company has disciplined focus of R&D resources on its next-generation IL-1 inhibitor pipeline (KPL-387 and KPL-1161), following discontinuation of other clinical programs.
Cyborg Score Rationale
The company achieved full-year net income of $59.0 million, a landmark reversal from a $43.2 million net loss in 2024. As of December 31, 2025, Kiniksa had $414.1 million of cash, cash equivalents, and short-term investments and no debt. However, Kiniksa's growth trajectory remains highly dependent on continued commercial success of ARCALYST, creating significant asset concentration risk.
Top Insights
ARCALYST 2026 net product revenue expected to be $900 - $920 million, representing ~34% YoY growth guidance
Operating margin made dramatic swing from negative 10.8% in 2024 to positive 11.4% in 2025, underscoring scalability of commercial model
KPL-387 Phase 2/3 clinical trial data expected in second half of 2026
KPL-1161 Phase 1 first-in-human clinical trial expected to initiate by end of 2026
Named Competitors
IL-1 Pathway Inhibitors — Various companies pursuing IL-1 inhibition for cardiovascular and inflammatory conditions
Cardiovascular Specialty Pharma — Competitors in rare cardiovascular disease treatment space
Recent Developments
(February 2026) Reported full-year 2025 results with $677.5M ARCALYST revenue (62% YoY growth) and achieved profitability
(February 2026) Issued 2026 ARCALYST revenue guidance of $900-$920M
(January 2026) Provided corporate update highlighting KPL-387 Phase 2/3 progress with data expected in 2H 2026
Open the full interactive Kiniksa Pharmaceuticals International, plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.